WO2023054315A1 - コラーゲントリペプチド製造又は軟骨分解のための酵素剤 - Google Patents
コラーゲントリペプチド製造又は軟骨分解のための酵素剤 Download PDFInfo
- Publication number
- WO2023054315A1 WO2023054315A1 PCT/JP2022/035843 JP2022035843W WO2023054315A1 WO 2023054315 A1 WO2023054315 A1 WO 2023054315A1 JP 2022035843 W JP2022035843 W JP 2022035843W WO 2023054315 A1 WO2023054315 A1 WO 2023054315A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- collagenase
- amino acid
- activity
- acid sequence
- enzyme
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 110
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 109
- 102000008186 Collagen Human genes 0.000 title claims abstract description 49
- 108010035532 Collagen Proteins 0.000 title claims abstract description 49
- 229920001436 collagen Polymers 0.000 title claims abstract description 49
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 28
- 230000008355 cartilage degradation Effects 0.000 title claims abstract description 14
- 229940088598 enzyme Drugs 0.000 claims abstract description 109
- 108060005980 Collagenase Proteins 0.000 claims abstract description 104
- 102000029816 Collagenase Human genes 0.000 claims abstract description 103
- 229960002424 collagenase Drugs 0.000 claims abstract description 93
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 66
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 43
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims description 73
- 230000002255 enzymatic effect Effects 0.000 claims description 38
- 108010010803 Gelatin Proteins 0.000 claims description 34
- 239000008273 gelatin Substances 0.000 claims description 34
- 229920000159 gelatin Polymers 0.000 claims description 34
- 235000019322 gelatine Nutrition 0.000 claims description 34
- 235000011852 gelatine desserts Nutrition 0.000 claims description 34
- 235000013372 meat Nutrition 0.000 claims description 25
- 241001134775 Lysinibacillus fusiformis Species 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 210000000845 cartilage Anatomy 0.000 claims description 20
- DHDOADIPGZTAHT-YUMQZZPRSA-N Gly-Glu-Arg Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DHDOADIPGZTAHT-YUMQZZPRSA-N 0.000 claims description 13
- 210000000988 bone and bone Anatomy 0.000 claims description 9
- 241000283690 Bos taurus Species 0.000 claims description 7
- 241000287828 Gallus gallus Species 0.000 claims description 7
- 230000000593 degrading effect Effects 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 235000013305 food Nutrition 0.000 abstract description 8
- 108091005804 Peptidases Proteins 0.000 abstract description 5
- 239000004365 Protease Substances 0.000 abstract description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 44
- 108090000623 proteins and genes Proteins 0.000 description 38
- 150000007523 nucleic acids Chemical class 0.000 description 30
- 108020004707 nucleic acids Proteins 0.000 description 27
- 102000039446 nucleic acids Human genes 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 19
- 239000000872 buffer Substances 0.000 description 18
- 230000014616 translation Effects 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 150000001413 amino acids Chemical group 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 244000005700 microbiome Species 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 238000013519 translation Methods 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 241000251468 Actinopterygii Species 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 8
- 235000019688 fish Nutrition 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 238000001243 protein synthesis Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 239000007990 PIPES buffer Substances 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 239000008351 acetate buffer Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 235000013330 chicken meat Nutrition 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 241000235343 Saccharomycetales Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 238000012136 culture method Methods 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 4
- HVIBGVJOBJJPFB-OFQRNFBNSA-N Gly-Pro-Hyp Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)C(O)CC1 HVIBGVJOBJJPFB-OFQRNFBNSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 108010017349 glycyl-prolyl-hydroxyproline Proteins 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 239000005909 Kieselgur Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000006173 Good's buffer Substances 0.000 description 2
- 241000607259 Grimontia hollisae Species 0.000 description 2
- 241000193159 Hathewaya histolytica Species 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 2
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000003366 colagenolytic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229960001790 sodium citrate Drugs 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 2
- 235000019801 trisodium phosphate Nutrition 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 1
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 101100179048 Arabidopsis thaliana IAA3 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010013295 Microbial collagenase Proteins 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 206010034203 Pectus Carinatum Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108010091431 meat tenderizer Proteins 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108010057757 methionyl-tRNA formyltransferase Proteins 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24003—Microbial collagenase (3.4.24.3)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/40—Meat products; Meat meal; Preparation or treatment thereof containing additives
- A23L13/48—Addition of, or treatment with, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/70—Tenderised or flavoured meat pieces; Macerating or marinating solutions specially adapted therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/70—Tenderised or flavoured meat pieces; Macerating or marinating solutions specially adapted therefor
- A23L13/72—Tenderised or flavoured meat pieces; Macerating or marinating solutions specially adapted therefor using additives, e.g. by injection of solutions
- A23L13/74—Tenderised or flavoured meat pieces; Macerating or marinating solutions specially adapted therefor using additives, e.g. by injection of solutions using microorganisms or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6416—Metalloendopeptidases (3.4.24)
Definitions
- the present invention relates to an enzymatic agent for collagen tripeptide production or cartilage degradation, which contains collagenase as an active ingredient, and uses thereof.
- CTP collagen tripeptide
- collagenases In order to efficiently produce CTP, a protease (collagenase) that can specifically cleave collagen or gelatin at the Gly residue position and degrade it to tripeptides is useful.
- collagenases include collagenases derived from the genera Clostridium and Vibrio, and Bacillus cereus collagenase (belonging to Microbial collagenase (EC.3.4.24.3)).
- EC.3.4.24.3 Bacillus cereus collagenase
- a collagenase derived from the genus Streptomyces is known as a collagenase that can be used for food (Patent Document 1), but it is unknown whether it can be used for CTP production. Also, existing collagenases generally have poor stability. Vibrio hollisae-derived collagenase (Vibrio sp 1706B strain-derived collagenase in Patent Document 2) is known as a microorganism-derived collagenase that is said to have excellent stability and high specific activity. (Patent Document 2, Patent Document 3). However, the heat stability of collagenase derived from Vibrio hollisae is 30°C or less, which is insufficient for practical use.
- collagenases with different properties.
- two different collagenase types (I, II) are known among collagenases from the genus Clostridium histolyticum, and collagenase I has higher activity on collagen and gelatin than collagenase II, and is capable of producing short peptides. It has low activity against (Patent Document 4).
- Clostridium histolyticum-derived collagenase has a low degradation rate for cleaving CTP from collagen-like sequences (Patent Document 5).
- Collagenase suitable for producing CTP from collagen that can be used for food applications is required to have safe collagenase-producing bacteria, to have collagen-degrading or gelatin-degrading ability, and to have CTP-generating ability.
- high stability is also required, but no collagenase is known that satisfies such conditions and has been put to practical use.
- the object of the present invention is to provide a highly safe protease (collagenase) that is useful for food or medical applications, such as collagen tripeptide production or cartilage degradation, and uses thereof.
- a highly safe protease (collagenase) that is useful for food or medical applications, such as collagen tripeptide production or cartilage degradation, and uses thereof.
- the present inventors extensively screened enzymes derived from microorganisms, aiming to obtain a collagenase that has high CTP-producing ability, high cartilage-degrading ability, and high safety. As a result, it was found that a specific strain of Lysinibacillus fusiformis produced a collagenase that met the purpose.
- the collagenase exhibited collagenase-degrading ability and CTP-generating ability, and had high cartilage-degrading ability, and was highly industrially useful. According to the present invention, the following inventions are provided.
- An enzymatic agent for producing collagen tripeptide comprising as an active ingredient a collagenase comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence equivalent thereto.
- a collagenase consisting of an equivalent amino acid sequence has 90% or more identity with the amino acid sequence of SEQ ID NO: 1, and a collagenase consisting of the amino acid sequence of SEQ ID NO: 1 and Gly-Glu-Arg from bovine bone gelatin.
- the enzymatic agent according to ⁇ 1> which is a collagenase having the same production ability.
- ⁇ 3> The enzymatic agent according to ⁇ 1> or ⁇ 2>, wherein the collagenase is derived from Lysinibacillus fusiformis.
- An enzymatic agent for producing collagen tripeptide which is derived from Lysinibacillus fusiformis and contains collagenase having the following physicochemical properties as an active ingredient.
- Optimal temperature Around 40°C.
- Temperature stability The relative residual activity is 80% or more from 4°C to 40°C, and 10% or less at 50°C, with the activity at the treatment temperature showing the highest activity being 100%.
- Optimum pH The optimum pH is around 7.
- the relative residual activity is 80% or more in the range of pH 6 to 8, and 10% or less at pH 5, with the activity at the processing pH where the activity was highest being 100%.
- An enzymatic agent for meat tenderization and/or cartilage degradation comprising as an active ingredient a collagenase comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence equivalent thereto.
- Collagenase consisting of an equivalent amino acid sequence has an identity of 90% or more with the amino acid sequence of SEQ ID NO: 1, and is equivalent to the collagenase consisting of the amino acid sequence of SEQ ID NO: 1 in decomposing chicken cartilage.
- Optimal temperature Around 40°C.
- Temperature stability The relative residual activity is 80% or more from 4°C to 40°C, and 10% or less at 50°C, with the activity at the treatment temperature showing the highest activity being 100%.
- Optimum pH The optimum pH is around 7.
- the relative residual activity is 80% or more in the range of pH 6 to 8, and 10% or less at pH 5, with the activity at the processing pH where the activity was highest being 100%.
- a method for producing a collagen tripeptide comprising allowing the enzymatic agent according to any one of ⁇ 1> to ⁇ 4> to act on collagen or gelatin.
- a method for tenderizing meat and/or degrading cartilage which comprises allowing the enzymatic agent according to any one of ⁇ 5> to ⁇ 8> to act on meat and/or cartilage.
- FIG. 1 shows the optimum temperature of collagenase derived from Lysinibacillus fusiformis 7128 strain.
- Figure 2 shows the temperature stability of collagenase from Lysinibacillus fusiformis strain 7128.
- FIG. 3 shows the optimum pH of collagenase derived from Lysinibacillus fusiformis 7128 strain.
- Figure 4 shows pH stability of collagenase from Lysinibacillus fusiformis strain 7128.
- FIG. 5 shows the results of confirming the production ability (fish gelatin) of Gly-Pro-Hyp, which is a collagen tripeptide.
- FIG. 1 shows the optimum temperature of collagenase derived from Lysinibacillus fusiformis 7128 strain.
- Figure 2 shows the temperature stability of collagenase from Lysinibacillus fusiformis strain 7128.
- FIG. 3 shows the optimum pH of collagenase derived from Lysin
- FIG. 6 shows the results of confirming the production ability (fish gelatin) of Gly-Pro-Ala, which is a collagen tripeptide.
- FIG. 7 shows the results of confirming the production ability (fish gelatin) of Gly-Glu-Arg, which is a collagen tripeptide.
- FIG. 8 shows the results of confirming the ability (bovine bone gelatin) to produce Gly-Glu-Arg, which is a collagen tripeptide.
- FIG. 9 shows the results of measuring cartilage degradation.
- a first aspect of the present invention relates to an enzyme agent for collagen tripeptide production or meat tenderization and/or cartilage degradation.
- the enzyme agent of the present invention (hereinafter also referred to as “this enzyme agent”) contains collagenase (hereinafter also referred to as “this enzyme”) as an active ingredient.
- This enzyme contains collagenase (hereinafter also referred to as "this enzyme") as an active ingredient.
- the enzymatic agent of the present invention is useful in collagen tripeptide production or meat tenderization and/or cartilage degradation (details will be described later).
- the active ingredient, collagenase, ie, the present enzyme consists of the amino acid sequence shown in SEQ ID NO: 1 or an amino acid sequence equivalent thereto.
- equivalent amino acid sequence refers to a partial difference from the reference amino acid sequence (amino acid sequence of SEQ ID NO: 1), but the difference has a substantial effect on protein function (here, collagenolytic activity). means an amino acid sequence that does not give a do. Therefore, enzymes with equivalent amino acid sequences catalyze the degradation reaction of collagen, have the ability to produce Gly-Glu-Arg from bovine bone gelatin, and/or have the ability to degrade chicken cartilage.
- the collagen degradation activity, Gly-Glu-Arg production ability, and chicken cartilage degradability are not particularly limited as long as the collagenase function can be exhibited.
- Equivalent ability to produce Gly-Glu-Arg from bovine bone gelatin means having ability to produce ⁇ 10%, preferably ⁇ 5% compared to collagenase having the reference amino acid sequence.
- Equivalent chicken cartilage resolution refers to ⁇ 10% resolution, preferably ⁇ 5% resolution compared to collagenase having the standard amino acid sequence.
- the amino acid sequence of SEQ ID NO: 1 is the amino acid sequence (mature form) of collagenase derived from Lysinibacillus fusiformis.
- the amino acid sequence of Lysinibacillus fusiformis-derived collagenase, which also has a signal peptide and a pro-sequence, is shown in SEQ ID NO:2.
- Partial difference in amino acid sequence includes, for example, deletion or substitution of one or more amino acids in the amino acids constituting the amino acid sequence, addition or insertion of one or more amino acids to the amino acid sequence, or caused by any combination of Partial differences in the amino acid sequences are permissible as long as collagenolytic activity, Gly-Glu-Arg production ability, and/or poultry cartilage-degrading activity are maintained (activity may vary slightly). As long as this condition is satisfied, the positions where the amino acid sequences differ are not particularly limited. In addition, differences in amino acid sequences may occur at multiple sites (sites).
- the number of amino acids that cause a partial difference in the amino acid sequence is, for example, a number corresponding to about 20% or less, preferably about 15% or less, more preferably a number corresponding to all amino acids constituting the amino acid sequence.
- a number corresponding to about 0.3% or less is preferred, and a number corresponding to about 0.1% or less is more preferred.
- an equivalent protein is, for example, about 80% or more, preferably about 85% or more, more preferably about 90% or more, more preferably about 95% or more, more preferably about 97% or more, or more, than the reference amino acid sequence. preferably about 98% or more, more preferably about 99% or more, more preferably about 99.3% or more, more preferably about 99.5% or more, more preferably about 99.7% or more, even more preferably about 99% .9% or greater identity.
- partial difference in amino acid sequence is 1 to 40 (preferably 1 to 30, more preferably 1 to 10, more preferably 1 to 40) among the amino acids constituting the amino acid sequence.
- 1 to 40 (preferably 1 to 30, more preferably 1 ⁇ 10, more preferably 1 to 7, still more preferably 1 to 5, still more preferably 1 to 3) amino acid addition, insertion, or a combination thereof resulting in mutation (change) in the amino acid sequence It is happening.
- an equivalent amino acid sequence is obtained by making conservative amino acid substitutions at amino acid residues that are not essential for degrading collagen.
- conservative amino acid substitution refers to substitution of an amino acid residue with an amino acid residue having a side chain with similar properties.
- Amino acid residues can have, depending on their side chain, a basic side chain (e.g. lysine, arginine, histidine), an acidic side chain (e.g. aspartic acid, glutamic acid), an uncharged polar side chain (e.g. glycine, asparagine, glutamine, serine, threonine, tyrosine). , cysteine), nonpolar side chains (e.g.
- alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g. threonine, valine, isoleucine), aromatic side chains (e.g. tyrosine, phenylalanine, Tryptophan, histidine) are classified into several families. Conservative amino acid substitutions are preferably between amino acid residues within the same family.
- the identity (%) of two amino acid sequences can be determined, for example, by the following procedure. First, the two sequences are aligned for optimal comparison (eg, gaps may be introduced in the first sequence to optimize alignment with the second sequence). When the molecule (amino acid residue) at a particular position in the first sequence is the same as the molecule at the corresponding position in the second sequence, the molecules at that position are said to be identical.
- the collagenase which is the active ingredient of the enzymatic agent, that is, the enzyme may be part of a larger protein (eg, fusion protein).
- Additional sequences in the fusion protein include, for example, sequences that aid in purification such as multiple histidine residues, additional sequences that ensure stability during recombinant production, and the like.
- This enzyme can be obtained by culturing a microorganism that produces the collagenase (collagenase-producing strain), for example, Lysinibacillus fusiformis.
- Collagenase-producing strains may be wild strains or mutant strains (for example, mutant strains obtained by ultraviolet irradiation).
- This enzyme can be prepared from the culture solution and/or cells of microorganisms that produce this enzyme.
- Culture conditions and culture methods are not particularly limited as long as the present enzyme is produced. That is, on the condition that the present enzyme is produced, a method and culture conditions suitable for culturing the microorganism to be used can be appropriately set.
- a culture method either liquid culture or solid culture may be used, but liquid culture is preferably used. Taking liquid culture as an example, the culture conditions will be described.
- the medium is not particularly limited as long as it allows the microorganisms to be used to grow.
- glucose, sucrose, gentiobiose, soluble starch, glycerin, dextrin, molasses carbon sources such as organic acids, ammonium sulfate, ammonium carbonate, ammonium phosphate, ammonium acetate, or gelatin, peptone, yeast extract, corn steep liquor.
- Casein hydrolyzate, wheat bran, nitrogen sources such as meat extracts, and inorganic salts such as potassium salts, magnesium salts, sodium salts, phosphates, manganese salts, iron salts, zinc salts, etc. can be used.
- the pH of the medium is adjusted to, for example, about 3 to 8, preferably about 4 to 7, and the culture temperature is usually about 20 to 40°C, preferably about 25 to 35°C, for 1 to 20 days, preferably 3 to 3. Incubate under aerobic conditions for about 10 days.
- a shake culture method and an aerobic submerged culture method using a jar fermenter can be used.
- the target enzyme is recovered from the culture solution or the bacterial cells.
- the present enzyme can be obtained by separating and purifying by appropriately combining various chromatographic techniques.
- the present enzyme can be obtained by, for example, crushing the cells by pressure treatment, ultrasonic treatment, etc., followed by separation and purification in the same manner as described above.
- the series of steps may be performed after collecting the bacterial cells from the culture solution in advance by filtration, centrifugation, or the like.
- This enzyme can be easily prepared by genetic engineering techniques. For example, it can be prepared by transforming a suitable host cell (eg, E. coli) with a DNA encoding the present enzyme and recovering the protein expressed in the transformant. The recovered protein is appropriately purified depending on the purpose. Various modifications are possible if the target enzyme is obtained as a recombinant protein in this way. For example, if a DNA encoding this enzyme and other suitable DNA are inserted into the same vector and a recombinant protein is produced using the vector, the recombinant protein consists of any peptide or protein linked thereto. This enzyme can be obtained. In addition of sugar chains and/or lipids, or modification that causes N-terminal or C-terminal processing may be performed. Such modifications enable extraction of recombinant proteins, simplification of purification, addition of biological functions, and the like.
- a suitable host cell eg, E. coli
- the recovered protein is appropriately purified depending on the purpose.
- the target enzyme is obtained as a
- an appropriate host-vector system is usually used to express the gene and recover the expression product (this enzyme), but a cell-free synthesis system may also be used.
- the "cell-free synthesis system does not use living cells, but ribosomes derived from living cells (or obtained by genetic engineering techniques), It refers to the in vitro synthesis of mRNA or protein encoded by a template nucleic acid (DNA or mRNA) using transcription/translation factors.
- a cell-free synthesis system generally uses a cell extract obtained by purifying a cell lysate as necessary.
- Cell extracts generally contain various factors such as ribosomes and initiation factors necessary for protein synthesis, and various enzymes such as tRNA. When synthesizing proteins, other substances necessary for protein synthesis such as various amino acids, energy sources such as ATP and GTP, and creatine phosphate are added to the cell extract. Of course, ribosomes, various factors, and/or various enzymes prepared separately may be supplemented as necessary during protein synthesis.
- cell-free transcription/translation system is used interchangeably with cell-free protein synthesis system, in vitro translation system or in vitro transcription/translation system.
- In vitro translation systems use RNA as a template to synthesize proteins. Total RNA, mRNA, in vitro transcripts and the like are used as template RNA.
- the other in vitro transcription/translation system uses DNA as a template.
- the template DNA should contain a ribosome binding region and preferably contains a suitable terminator sequence.
- conditions are set such that factors necessary for each reaction are added so that the transcription reaction and the translation reaction proceed continuously.
- the purified enzyme obtained as described above can be powdered by, for example, freeze-drying, vacuum-drying, or spray-drying. At that time, the purified enzyme may be dissolved in advance in acetate buffer, phosphate buffer, triethanolamine buffer, Tris-HCl buffer, or GOOD buffer. Preferably, acetate buffers, phosphate buffers and triethanolamine buffers can be used.
- the GOOD buffer includes PIPES, MES or MOPS.
- the degree of purification of the enzyme is not particularly limited, for example, the Pz-peptide degradation activity is 1 to 20000 (U/g), preferably 10 to 10000 (U/g), more preferably 100 to 1000 (U/g). can be purified to Moreover, the final form may be liquid or solid (including powder).
- Licinibacillus fusiformis-derived collagenase consisting of the amino acid sequence of SEQ ID NO: 1 were determined as follows (for details, see Examples below). Therefore, this enzyme can also be specified by the following enzymatic chemical properties. Details of conditions for measuring collagenase activity, procedures for measuring collagenase activity, and the like when evaluating each enzymatic chemical property will be described in Examples below.
- This enzyme is a collagenase that acts on collagen and gelatin to produce collagen tripeptides.
- the optimum pH of this enzyme is about 7.
- the optimum pH is, for example, pH 4-6 in acetate buffer, pH 6-7 in PIPES buffer, and pH 7-9 in Tris-HCl buffer (Tris-HCl). It is judged based on the measured results.
- pH stability This enzyme exhibits stable activity in the pH range of pH6-8. For example, if the pH of the enzyme solution to be treated is within this range, the activity will be 70% or more of the maximum activity after treatment at 30°C for 30 minutes, while at pH 5 it will decrease to 10% or less of the maximum activity. This is useful in that the enzyme can be deactivated with relatively weak acidity so that the reaction does not proceed excessively. pH stability is measured, for example, in acetate buffer in the pH range of pH 4-6, in PIPES buffer in the pH range of pH 6-7, in Tris-HCl buffer (Tris-HCl) in the pH range of pH 7-9, In the pH range of pH 9-11, judgment is made based on the results of measurement in glycine buffer.
- Collagen tripeptide Gly-X-Y CTP
- Gly-Pro-Hyp Gly-Pro-Hyp
- Gly-Pro-Ala Gly-Glu-Arg
- Gly (glycine) Gly (glycine) at the N-terminus
- This enzyme is characterized by a particularly high production of Gly-Glu-Arg when acted on collagen or gelatin.
- the content of the active ingredient (the present enzyme) in the present enzymatic agent is not particularly limited. Amount can be set or adjusted.
- the enzymatic agent of the present invention is usually solid (for example, granules, powders, immobilized enzymes obtained by immobilizing the enzyme on the surface or inside of a material such as silica or porous polymer) or liquid. provided.
- the present enzyme preparation may contain excipients, buffers, suspending agents, stabilizers, preservatives, preservatives, physiological saline, and the like. Examples of excipients that can be used include lactose, sorbitol, D-mannitol, maltodextrin, and sucrose.
- Phosphate, citrate, acetate and the like can be used as buffers.
- Propylene glycol, ascorbic acid and the like can be used as stabilizers.
- Preservatives that can be used include phenol, benzalkonium chloride, benzyl alcohol, chlorobutanol, methylparaben, and the like.
- antiseptics benzalkonium chloride, paraoxybenzoic acid, chlorobutanol and the like can be used.
- the present enzyme may be produced by obtaining a gene encoding the present enzyme and expressing the gene.
- the gene encoding this enzyme consists of DNA encoding the amino acid sequence of SEQ ID NO:1.
- Specific examples of this aspect are DNA consisting of the nucleotide sequence shown in SEQ ID NO:3 and DNA consisting of the nucleotide sequence shown in SEQ ID NO:4.
- the former DNA (SEQ ID NO: 3) encodes only the mature form amino acid sequence (SEQ ID NO: 1)
- the latter DNA (SEQ ID NO: 4) contains the mature form (SEQ ID NO: 1 amino acid sequence), It encodes a signal peptide and prosequence.
- the gene encoding this enzyme is typically used to prepare this enzyme. According to the genetic engineering preparation method using the gene encoding this enzyme, it is possible to obtain this enzyme in a more homogeneous state. In addition, the method can be said to be a suitable method for preparing a large amount of the present enzyme. The use of the gene encoding this enzyme is not limited to the preparation of this enzyme.
- the nucleic acid can be used as an experimental tool for elucidating the mechanism of action of the present enzyme, or as a tool for designing or producing mutants (variants) of the present enzyme.
- the term "gene encoding the present enzyme” refers to a nucleic acid from which the present enzyme is obtained when the gene is expressed, not to mention nucleic acids having a base sequence corresponding to the amino acid sequence of the present enzyme. , also includes nucleic acids that have sequences that do not encode amino acid sequences added to such nucleic acids. Codon degeneracy is also taken into account.
- nucleic acids For nucleic acids, standard genetic engineering techniques, molecular biological techniques, biochemical techniques, chemical synthesis, and PCR (e.g., overlap PCR) are performed with reference to the sequence information disclosed in the present specification or the attached sequence listing. Alternatively, it can be prepared in an isolated state by a combination thereof.
- a nucleic acid that has the same function as the protein encoded by the enzyme, but has a different base sequence in part (hereinafter referred to as "equivalent nucleic acid")
- a base sequence that defines an equivalent nucleic acid is also referred to as an "equivalent base sequence"
- An example of an equivalent nucleic acid is a base sequence containing one or more base substitutions, deletions, insertions, additions, or inversions based on the base sequence of the nucleic acid encoding the present enzyme of the present invention, which is characteristic of the present enzyme.
- DNA encoding a protein having a specific enzymatic activity (ie, collagenase activity). Substitution or deletion of bases may occur at multiple sites.
- the term "plurality” as used herein means, for example, 2 to 40 bases, preferably 2 to 20 bases, more preferably 2 to 10 bases, although it varies depending on the positions and types of amino acid residues in the three-dimensional structure of the protein encoded by the nucleic acid. is.
- the equivalent nucleic acid is, for example, 90% or more, preferably 92% or more, more preferably 94% or more, still more preferably 96% or more, still more preferably 96% or more, relative to the reference base sequence (SEQ ID NO: 3 or SEQ ID NO: 4) have about 98% or greater identity, most preferably 99% or greater identity.
- Equivalent nucleic acids such as those described above can be obtained by, for example, restriction enzyme treatment, treatment with exonuclease or DNA ligase, site-directed mutagenesis (Molecular Cloning, Third Edition, Chapter 13, Cold Spring Harbor Laboratory Press, New York) or random mutation. It can be obtained by introducing a mutation by an introduction method (Molecular Cloning, Third Edition, Chapter 13, Cold Spring Harbor Laboratory Press, New York). Equivalent nucleic acids can also be obtained by other methods such as ultraviolet irradiation.
- nucleic acid having a nucleotide sequence complementary to the nucleotide sequence of the gene encoding the present enzyme of the present invention may be used. Still another aspect of the present invention is at least about 90%, 92%, 94%, 96%, 98% or 99% of the nucleotide sequence of the gene encoding the present enzyme of the present invention, or the nucleotide sequence complementary thereto Nucleic acids with % identical base sequences are provided.
- a nucleic acid having a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence complementary to the nucleotide sequence of the gene encoding the present enzyme of the present invention or its equivalent nucleotide sequence may be used. good.
- stringent conditions refers to conditions under which so-called specific hybrids are formed and non-specific hybrids are not formed. Such stringent conditions are known to those of skill in the art, see, for example, Molecular Cloning (Third Edition, Cold Spring Harbor Laboratory Press, New York) and Current protocols in molecular biology (edited by Frederick M. Ausubel et al., 1987). can be set.
- Stringent conditions include, for example, a hybridization solution (50% formamide, 10 ⁇ SSC (0.15M NaCl, 15mM sodiumcitrate, pH 7.0), 5 ⁇ Denhardt solution, 1% SDS, 10% dextran sulfate, 10 ⁇ g/ml denatured salmon Sperm DNA, 50 mM phosphate buffer (pH 7.5)) is used for incubation at about 50°C, followed by washing with 0.1 x SSC, 0.1% SDS at about 65°C.
- a hybridization solution 50% formamide, 10 ⁇ SSC (0.15M NaCl, 15mM sodiumcitrate, pH 7.0
- 5 ⁇ Denhardt solution 1% SDS
- 10% dextran sulfate 10 ⁇ g/ml denatured salmon Sperm DNA
- 50 mM phosphate buffer pH 7.5
- Further preferred stringent conditions include, for example, 50% formamide, 5 ⁇ SSC (0.15M NaCl, 15 mM sodiumcitrate, pH 7.0), 1 ⁇ Denhardt solution, 1% SDS, 10% dextran sulfate, 10 ⁇ g/ml as a hybridization solution. Conditions using denatured salmon sperm DNA, 50 mM phosphate buffer (pH 7.5)) can be mentioned.
- nucleic acid having a nucleotide sequence of the gene encoding the present enzyme of the present invention or a part of the nucleotide sequence complementary thereto may be used.
- a nucleic acid fragment can be used for detecting, identifying and/or amplifying a nucleic acid having the base sequence of the gene encoding the present enzyme of the present invention.
- a nucleic acid fragment is, for example, a continuous nucleotide portion (for example, about 10 to about 100 bases long, preferably about 20 to about 100 bases long, more preferably about 30 to about 100 bases long) in the nucleotide sequence of the gene encoding the present enzyme of the present invention. base length) is designed to include at least a portion that hybridizes.
- Nucleic acid fragments can be labeled when used as probes. For example, fluorescent substances, enzymes, and radioactive isotopes can be used for labeling.
- a recombinant DNA containing the above-described gene may be used.
- Recombinant DNA is provided, for example, in the form of a vector.
- vector refers to a nucleic acid molecule capable of transporting a nucleic acid inserted into it into a target such as a cell.
- E. coli host vectors include M13 phage or variants thereof, ⁇ phage or variants thereof, pBR322 or variants thereof (pB325, pAT153, pUC8, etc.), and yeast hosts include pYepSec1, pMFa, pYES2.
- yeast hosts include pYepSec1, pMFa, pYES2.
- vectors that use insect cells as hosts include pAc and pVL
- vectors that use mammal cells as hosts include pCDM8 and pMT2PC.
- the vector is preferably an expression vector.
- expression vector refers to a vector into which a nucleic acid inserted therein can be introduced into a target cell (host cell) and expressed in the cell.
- An expression vector usually contains a promoter sequence required for expression of the inserted nucleic acid, an enhancer sequence that promotes expression, and the like.
- Expression vectors containing selectable markers can also be used. When such an expression vector is used, the presence or absence (and degree of introduction) of the expression vector can be confirmed using a selection marker.
- Insertion of nucleic acids into vectors, insertion of selectable marker genes (if necessary), insertion of promoters (if necessary), etc. can be performed using standard recombinant DNA techniques (e.g., Molecular Cloning, Third Edition, 1.84, Cold Spring Harbor Laboratory Press, New York, a well-known method using restriction enzymes and DNA ligase).
- microorganisms such as Escherichia coli (Escherichia coli), Bacillus subtilis (Bacillus subtilis), and budding yeast (Saccharomyces cerevisiae) from the viewpoint of ease of handling.
- Escherichia coli Escherichia coli
- Bacillus subtilis Bacillus subtilis
- budding yeast Sacharomyces cerevisiae
- Any host cell that is replicable and capable of expressing the gene of the present enzyme can be used.
- E. coli include E. coli BL21(DE3)pLysS when a T7 promoter is used, and E. coli JM109 when not.
- budding yeast include budding yeast SHY2, budding yeast AH22, and budding yeast INVSc1 (Invitrogen).
- microorganisms that possess recombinant DNA may be used.
- Microorganisms can be obtained by transfection or transformation using the vectors described above.
- the calcium chloride method J. Mol. Biol., Vol. 53, pp. 159 (1970)
- the Hanahan method J. Mol. Biology, Vol. 166, 557 (1983)
- the SEM method Gene, Vol. 96, p. 23 (1990)
- the method of Chung et al. Proceedings of the National Academy of Sciences of the USA, No. 86 2172 (1989)
- calcium phosphate coprecipitation method electroporation (Potter, H. et al., Proc. Natl. Acad. Sci. U.S.A. 81, 7161-7165 (1984))
- lipofection Felgner, et al., Proc. Natl. Acad. Sci. be able to.
- a further aspect of the present invention relates to use of the present enzymatic agent.
- a method for producing collagen tripeptide (CTP) (hereinafter referred to as “method for producing CTP”) is provided.
- the enzymatic agent is allowed to act on collagen or gelatin (denatured collagen).
- the present enzymatic agent is added to a collagen or gelatin solution, for example, under conditions of 20 to 50°C, preferably 30 to 40°C, for a predetermined time (for example, 1 hour to 48 hours, preferably 1 hour to 24 hours, more preferably 1 hour to 12 hours).
- Collagen tripeptide is produced as a result of the decomposition reaction by collagenase, which is the active ingredient of this enzymatic agent.
- the composition, ratio, etc. of CTP in the product may vary depending on the type and origin of the substrate (collagen or gelatin) used, but according to the production method of the present invention, a tripeptide having Gly at the N-terminus (e.g., , Gly-Pro-Hyp, Gly-Pro-Ala, Gly-Glu-Arg), ie CTP-containing, is obtained. It is also one of the characteristics of the present invention that CTP can be generated by using the present enzymatic agent alone. However, it is also possible to use other collagenase, protease, or peptidase in combination to improve production efficiency.
- the origin of the collagen/gelatin used is not particularly limited, and examples include fish, pigs, cows, and chickens. Commercially available collagen or gelatin may be used.
- the method for preparing collagen or gelatin is also not particularly limited. For example, raw materials (animal skin, bones, tendons, fish scales, etc.) are washed with water and dried, and then demineralized with hydrochloric acid or the like as necessary. After washing, crude collagen is treated with caustic soda, hydrochloric acid, or the like. get In addition, gelatin can be extracted by heat-treating the crude collagen.
- purification treatment for example, filtration, ion exchange, activated carbon treatment
- purification treatment for example, filtration, ion exchange, activated carbon treatment
- the second use of this enzymatic agent is to improve the quality of meat (softening of meat, etc.), preferably to improve the quality of meat containing cartilage or to decompose cartilage.
- Use of the enzymatic agent of the present invention can efficiently decompose cartilage, improve the texture of meat containing cartilage, and improve the texture of meat containing bone and cartilage. It can help separate the cartilage from the bone.
- the meat to be reacted with the enzyme is not particularly limited as long as it contains cartilage.
- the term "meat" is used to also include processed meat products.
- the method is to immerse the meat in the enzyme solution (solution of the enzyme agent), pressurize the meat to allow the enzyme solution to permeate the meat, or inject the enzyme solution into the meat.
- This enzymatic agent may be allowed to act on the meat by a method of injecting the enzymatic solution into the meat and tumbling (a treatment in which the enzymatic solution is mechanically permeated).
- the temperature conditions for the action are, for example, 4°C to 40°C, and may be 4°C to 30°C, 4°C to 25°C, or 4°C to 20°C, or 10°C to 40°C, 20°C to 40°C, 30°C to 40°C, or 35°C to 40°C.
- the action time is, for example, 1 hour to 1 day, and may be 1 hour to 12 hours, 1 hour to 6 hours, 1 hour to 3 hours, or 1 hour to 2 hours.
- ⁇ Reference example> Screening of collagenase-producing strains In order to find collagenases that can be used in food, we first screened the library of Amano Enzyme Co., Ltd. based on collagenase activity as a primary screening, and produced biosafety level 1 (BSL1) strains that showed high activity. 113 species of bacteria were selected.
- BSL1 biosafety level 1
- the culture supernatant of the selected 113 kinds of producing bacteria was reacted with gelatin, the content of peptides with Gly at the N-terminus in the reaction products was evaluated, and 19 kinds of producing bacteria were selected.
- the total peptide amount was quantified with a ninhydrin reagent.
- the amount of peptides having Gly at the N-terminus was quantified using a collagen quantification kit (manufactured by Cosmo Bio).
- tripeptides were partially purified by gel filtration chromatography from the culture supernatants of 19 kinds of producing bacteria and gelatin reaction products, and then analyzed by reversed-phase chromatography. After partially purifying the culture supernatant of a promising producer from the analytical results, the collagenase-producing strain Lysinibacillus fusiformis 57413 was finally selected by evaluating the ability of collagenase to generate CTP.
- the amino acid sequence of SEQ ID NO: 5 is the amino acid sequence (mature form) of collagenase derived from Lysinibacillus fusiformis 57413 strain.
- SEQ ID NO: 6 shows the amino acid sequence of collagenase derived from Lysinibacillus fusiformis strain 57413, which also has a signal peptide and a pro-sequence.
- the DNA of SEQ ID NO: 7 encodes only the amino acid sequence of the mature form (SEQ ID NO: 5), and the DNA of SEQ ID NO: 8 contains the mature form (amino acid sequence of SEQ ID NO: 5), a signal peptide and a prosequence. is coded.
- Upstream forward primer: GGAAACAATCTAAATGTGTCT (SEQ ID NO: 9)
- Downstream Reverse primer: CCGCCTTTAAAGGCTCTCCGA (SEQ ID NO: 10)
- An expression plasmid was constructed by introducing the 57413 strain collagenase gene into pColdIII (manufactured by Takara Bio Inc.). Using the constructed expression plasmid, Escherichia coli BL21 was transformed by a conventional method. After culturing the transformant in LB medium (added with ampicillin) overnight at 37°C, the culture solution was inoculated into LB medium (added with ampicillin) at 1% volume and cultured at 37°C for 2 hours. Cultivation was performed overnight at °C.
- Collagenase activity was measured using PROTAZYME OL TABLETS (manufactured by Megazyme). 300 ⁇ L of the substrate solution suspended in 10 mM CaCl 2 200 mM Tris buffer per OL tablet was dispensed into a 1.5 mL tube with stirring and placed on ice. 100 ⁇ L of the enzyme solution was added to and mixed with the dispensed substrate solution, and the mixture was stirred for 30 minutes in a bioshaker set at 40° C. to cause a reaction. After 30 minutes of reaction, 1 mL of 2% trisodium phosphate solution was added to terminate the enzymatic reaction, followed by centrifugation (13000 g, 10 minutes). 200 ⁇ L of the supernatant was transferred to a microtiter plate and the absorbance at 590 nm was measured. The intensity of collagenase activity was judged by the 590 nm value that increased over 30 minutes.
- Casein degradation activity was measured using PROTAZYME AK TABLETS (manufactured by Megazyme). 300 ⁇ L of the substrate solution suspended in 10 mM CaCl2 200 mM Tris buffer per 1 tablet of AK was dispensed into a 1.5 mL tube while stirring and placed on ice. 100 ⁇ L of the enzyme solution was added to and mixed with the dispensed substrate solution, and the mixture was stirred for 30 minutes in a bioshaker set at 40° C. to cause a reaction. After 30 minutes of reaction, 1 mL of 2% trisodium phosphate solution was added to terminate the enzymatic reaction, followed by centrifugation (13000 g, 10 minutes). 200 ⁇ L of the supernatant was transferred to a microtiter plate and the absorbance at 590 nm was measured. The intensity of casein degradation activity was judged by the 590 nm value that increased in 30 minutes.
- 7128 Strain Collagenase Enzyme Powder A collagenase-producing Lysinibacillus fusiformis 7128 strain was selected according to "1. Screening for collagenase-producing strains" in Reference Example. Prepare 20 L of gelatin-containing medium (5% fish gelatin, 0.5% yeast extract, 2% NaCl) in a jar fermenter (30 L), steam sterilize, and add 200 mL of strain 7128 cultured overnight in SCD medium. , 30°C, 200 rpm agitation, and 0.5 vvm aeration for 36 hours. The resulting culture solution was subjected to diatomaceous earth filtration to obtain a crude enzyme solution.
- gelatin-containing medium 5% fish gelatin, 0.5% yeast extract, 2% NaCl
- This crude enzyme solution was filtered with 1% activated carbon to obtain a clear filtrate.
- This clarified filtrate was subjected to ultrafiltration (molecular weight cutoff: 6000), added with 4 times the amount of water, and desalted and concentrated. This was subjected to diatomaceous earth filtration and membrane filter filtration (0.45 ⁇ m), and the resulting filtrate was freeze-dried to obtain 7128 strain collagenase enzyme powder.
- sequence identification of 7128 strain collagenase The gene sequence was confirmed using primers designed based on the sequence information of collagenase derived from 57413 strain. Amino acid sequences were also determined from the gene sequences.
- the amino acid sequence of SEQ ID NO: 1 is the amino acid sequence (mature form) of collagenase derived from Lysinibacillus fusiformis 7128 strain.
- SEQ ID NO: 2 shows the amino acid sequence of collagenase derived from Lysinibacillus fusiformis strain 7128, which also has a signal peptide and a pro-sequence.
- the DNA of SEQ ID NO: 3 encodes only the amino acid sequence of the mature form (SEQ ID NO: 1), and the DNA of SEQ ID NO: 4 contains the mature form (amino acid sequence of SEQ ID NO: 1), a signal peptide and a prosequence. is coded.
- FIGS. 5-8 The results are shown in FIGS. 5-8. It was found that the enzyme of the present invention exhibits the ability to produce Gly-Pro-Hyp, Gly-Pro-Ala and Gly-Glu-Arg. In particular, it was found that the ability to produce Gly-Glu-Arg was excellent.
- Degree of cartilage degradation (weight of dry residue of blank - weight of enzyme-treated dry residue) / weight of dry residue of blank x 100
- the enzyme agent of the present invention contains collagenase derived from highly safe microorganisms as an active ingredient. Therefore, it is suitable for use in the fields of food and medical applications, and has high industrial utility value.
- SEQ ID NO: 9 Artificial Sequence Description: Forward Primer
- SEQ ID NO: 10 Artificial Sequence Description: Reverse Primer
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
<2> 等価なアミノ酸配列からなるコラゲナーゼが、配列番号1のアミノ酸配列と90%以上の同一性を有し、配列番号1のアミノ酸配列からなるコラゲナーゼと牛骨ゼラチンからのGly-Glu-Argの生成能が同等であるコラゲナーゼである、<1>に記載の酵素剤。
<3> コラゲナーゼがLysinibacillus fusiformis由来である、<1>又は<2>に記載の酵素剤。
<4> Lysinibacillus fusiformisに由来し、以下の理化学的性質を有するコラゲナーゼを有効成分とする、コラーゲントリペプチド製造のための酵素剤。
(1)至適温度:40℃付近である。
(2)温度安定性:最も活性が高かった処理温度での活性を100%とした相対残存活性について4℃から40℃までは80%以上であり、50℃では10%以下である。
(3)至適pH:至適pHは7付近である。
(4)pH安定性:最も活性が高かった処理pHでの活性を100%とした相対残存活性について、pHが6~8の範囲では80%以上であり、pH5では10%以下である。
<5> 配列番号1のアミノ酸配列又はそれと等価なアミノ酸配列からなるコラゲナーゼを有効成分とする、食肉軟化及び/又は軟骨分解のための酵素剤。
<6> 等価なアミノ酸配列からなるコラゲナーゼが、配列番号1のアミノ酸配列と90%以上の同一性を有し、配列番号1のアミノ酸配列からなるコラゲナーゼと鶏軟骨分解能が同等であるコラゲナーゼである、<5>に記載の酵素剤。
<7> コラゲナーゼがLysinibacillus fusiformis由来である、<5>又は<6>に記載の酵素剤。
<8> Lysinibacillus fusiformisに由来し、以下の理化学的性質を有するコラゲナーゼを有効成分とする、食肉軟化及び/又は軟骨分解のための酵素剤。
(1)至適温度:40℃付近である。
(2)温度安定性:最も活性が高かった処理温度での活性を100%とした相対残存活性について4℃から40℃までは80%以上であり、50℃では10%以下である。
(3)至適pH:至適pHは7付近である。
(4)pH安定性:最も活性が高かった処理pHでの活性を100%とした相対残存活性について、pHが6~8の範囲では80%以上であり、pH5では10%以下である。
<9> <1>から<4>の何れか一に記載の酵素剤をコラーゲン又はゼラチンに作用させることを特徴とする、コラーゲントリペプチドの製造方法。
<10> <5>から<8>の何れか一に記載の酵素剤を食肉及び/又は軟骨に作用させることを特徴とする、食肉軟化及び/又は軟骨分解方法。
本発明の第1の局面は、コラーゲントリペプチド製造あるいは食肉軟化及び/又は軟骨分解のための酵素剤に関する。本発明の酵素剤(以下、「本酵素剤」とも呼ぶ)は、有効成分としてコラゲナーゼ(以下、「本酵素」とも呼ぶ)を含有する。本発明の酵素剤は、コラーゲントリペプチド製造あるいは食肉軟化及び/又は軟骨分解において有用である(詳細は後述する)。有効成分のコラゲナーゼ、即ち本酵素は、配列番号1に示すアミノ酸配列又は当該アミノ酸配列と等価なアミノ酸配列からなる。ここでの「等価なアミノ酸配列」とは、基準のアミノ酸配列(配列番号1のアミノ酸配列)と一部で相違するが、当該相違がタンパク質の機能(ここではコラーゲン分解活性)に実質的な影響を与えていないアミノ酸配列のことを意味し、本発明においてはさらに、牛骨ゼラチンからのGly-Glu-Argの生成能が同等であるアミノ酸配列、または鶏軟骨分解能が同等であるアミノ酸配列を意味する。従って、等価なアミノ酸配列を有する酵素はコラーゲンの分解反応を触媒し、牛骨ゼラチンからのGly-Glu-Argの生成能を有するか、および/又は鶏軟骨分解能を有する。上記のコラーゲン分解活性、Gly-Glu-Argの生成能、および鶏軟骨分解能の程度は、コラゲナーゼとしての機能を発揮できる限り特に限定されない。但し、基準となるアミノ酸配列からなる酵素(配列番号1のアミノ酸配列を有する)と同程度又はそれよりも高いことが好ましい。牛骨ゼラチンからのGly-Glu-Argの生成能が同等とは、基準のアミノ酸配列を有するコラゲナーゼと比較して、±10%の生成能、好ましくは±5%の生成能を有することを言う。鶏軟骨分解能が同等とは、基準のアミノ酸配列を有するコラゲナーゼと比較して、±10%の分解能、好ましくは±5%の分解能を有することを言う。
本酵素はコラゲナーゼであり、コラーゲンやゼラチンに作用してコラーゲントリペプチドを生成する。
本酵素の至適温度は40℃である。
本酵素はTris-塩酸緩衝液中、pH7の条件下、40℃以下(0℃~40℃)の条件で30分処理しても実質的な活性の低下はない。上記条件下において、50℃~60℃の条件で30分処理した場合には、活性は10%以下に低下する。これは、反応が過度に進行しないように酵素を失活させる際に比較的低温で失活できる点で有用である。
本酵素の至適pHは約7である。至適pHは、例えば、pH4~6のpH域では酢酸緩衝液中、pH6~7のpH域ではPIPES緩衝液中、pH7~9のpH域ではTris-塩酸緩衝液(Tris-HCl)中で測定した結果を基に判断される。
本酵素はpH6~8のpH域で安定した活性を示す。例えば、処理に供する酵素溶液のpHがこの範囲内にあれば、30℃、30分の処理後、最大活性の70%以上の活性を示す一方、pH5では最大活性の10%以下に低下する。これは、反応が過度に進行しないように酵素を失活させる際に比較的弱酸性で失活できる点で有用である。pH安定性は、例えば、pH4~6のpH域では酢酸緩衝液中、pH6~7のpH域ではPIPES緩衝液中、pH7~9のpH域ではTris-塩酸緩衝液(Tris-HCl)中、pH9~11のpH域ではグリシン緩衝液中で測定した結果を基に判断される。
本酵素は、本酵素をコードする遺伝子を取得し、当該遺伝子を発現させることにより製造してもよい。一態様において本酵素をコードする遺伝子は、配列番号1のアミノ酸配列をコードするDNAからなる。当該態様の具体例は、配列番号3に示す塩基配列からなるDNA、及び配列番号4に示す塩基配列からなるDNAである。前者のDNA(配列番号3)は成熟体のアミノ酸配列(配列番号1)のみをコードするものであり、後者のDNA(配列番号4)は、成熟体(配列番号1のアミノ酸配列)に加え、シグナルペプチドとプロ配列をコードしている。
本発明の更なる局面は本酵素剤の用途に関する。第1の用途として、コラーゲントリペプチド(CTP)の製造方法(以下、「CTP製造方法」と呼ぶ)が提供される。本発明のCTP製造方法では本酵素剤をコラーゲン又はゼラチン(変性コラーゲン)に作用させる。例えば、本酵素剤をコラーゲン又はゼラチンの溶液に添加し、例えば20~50℃、好ましくは30~40℃の条件下、所定時間(例えば、1時間~48時間、好ましくは1時間~24時間、より好ましくは1時間~12時間)反応させる。本酵素剤の有効成分であるコラゲナーゼによる分解反応の結果、コラーゲントリペプチドが生成する。使用する基質(コラーゲン又はゼラチン)の種類や由来等によって、製造物中のCTPの組成や比率等は変動し得るが、本発明の製造方法によれば、GlyをN末端に有するトリペプチド(例えば、Gly-Pro- Hyp、Gly-Pro-Ala、Gly-Glu-Arg)を含有する組成物、即ちCTP含有物が得られる。本酵素剤単独での使用によってCTPを生成させることができることは本発明の特徴の一つでもある。但し、別のコラゲナーゼやプロテアーゼ、或いはペプチダーゼを併用し、製造効率の向上等を図ることも可能である。
1.コラゲナーゼ産生株のスクリーニング
食品利用可能なコラゲナーゼを見出すべく、まず1次スクリーニングとして天野エンザイム株式会社のライブラリーからコラゲナーゼ活性を指標にスクリーニングを実施し、高活性を示したバイオセーフティーレベル1(BSL1)生産菌113種を選抜した。
57413株をゼラチン含有培地(5%フィッシュゼラチン、0.5%酵母エキス、2%NaCl)で、30℃、2日間、通気撹拌培養した。得られた培養液を遠心分離した後、上清を珪藻土濾過して粗酵素液を得た。さらに疎水クロマトグラフィー(Pheny HP, GEヘルスケア ライフサイエンス社製)、陰イオン交換クロマトグラフィー(DEAE FF, GEヘルスケア ライフサイエンス社製)を用いて酵素を精製した。
57413株をSCD液体培地にて一晩30℃で培養を行った後、菌体を遠心分離にて回収した。回収した菌体をTE緩衝液で懸濁し、NucleoSpin(登録商標) Microbial DNA(タカラバイオ株式会社製)を用いてDNAを抽出した。抽出したDNAを鋳型として、以下の上流及び下流プライマーとPrimeSTAR(登録商標) Max DNA Polymerase(タカラバイオ株式会社製)を用いてPCRを実施した。増幅したPCR産物を、構造遺伝子内外と相同性のあるプライマーを用いた塩基配列解析を実施することで、配列を確認した。
配列番号5のアミノ酸配列はLysinibacillus fusiformis57413株由来のコラゲナーゼのアミノ酸配列(成熟体)である。尚、シグナルペプチドとプロ配列も有する、Lysinibacillus fusiformis57413株由来のコラゲナーゼのアミノ酸配列を配列番号6に示す。
配列番号7のDNAは、成熟体のアミノ酸配列(配列番号5)のみをコードするものであり、配列番号8のDNAは、成熟体(配列番号5のアミノ酸配列)に加え、シグナルペプチドとプロ配列をコードしている。
下流:リバースプライマー: CCGCCTTTAAAGGCTCTCCGA(配列番号10)
57413株コラゲナーゼ遺伝子をpColdIII(タカラバイオ株式会社製)に導入することで、発現プラスミドを構築した。構築した発現プラスミドを用い、常法にて大腸菌BL21を形質転換した。形質転換体をLB培地(アンピシリン添加)で一晩37℃で培養後、その培養液をLB培地(アンピシリン添加)に1%容量接種し、37℃で2時間培養後、IPTGを添加し、15℃で一晩培養を行った。この培養液から遠心分離にて菌体を回収し、超音波破砕にて菌体を破砕した後、遠心分離にて上清を回収し、組換え粗酵素液とした。この粗酵素液の酵素活性を以下の測定方法で確認したところ、コラーゲン分解活性、pz-peptide分解活性、及びCTP生成能を有していることがわかった。さらに、カゼイン分解活性を有しておらず、コラーゲンやゼラチンに特異的に作用する可能性が極めて高い。
1mg/mL Pz-peptide (Pz-Pro-Leu-Gly-Pro-D-Arg-OH, BACHEM製), 20mM CaCl2 200mM トリス塩酸緩衝液900μLに酵素液100μLを添加し、37℃で反応開始した。反応開始後10分と20分で反応液を100μLサンプリングし、25mMクエン酸液200μLに添加することで反応停止液とした。この反応停止液に1mLの酢酸エチルを添加して10秒間撹拌後に遠心分離(12000×g 10分間)し、上清の酢酸エチル層を回収した。回収した上清の酢酸エチル層の320nmの吸光度を測定することで、コラゲナーゼによって遊離したPz-Pro-Leu量を求めた。酵素活性は、10分後と20分後のPz-Pro-Leu生成量から1分間当たりのPz-Pro-Leu生成速度を算出することで評価した。1分間に1μmol Pz peptideを分解する(1μmol Pz-Pro-Leuを遊離する)酵素量を1Uと定義した。
コラゲナーゼ活性はPROTAZYME OL TABLETS (Megazyme社製)を用いて測定した。OL1錠に対して10mMCaCl2200mMトリス緩衝液にて懸濁した基質溶液を撹拌しながら1.5mLチューブに300μL分注し氷上に置いた。分注した基質溶液に酵素液100μLを添加混合し、40℃に合わせたバイオシェーカーにて30分間撹拌することで反応させた。反応30分後、2%リン酸三ナトリウム溶液1mLを添加することで酵素反応を停止させ、遠心分離(13000g, 10分間)した。上清200μLをマイクロタイタープレートに移し、590nmの吸光度を測定した。30分間で上昇した590nm値でコラゲナーゼ活性の強度を判断した。
カゼイン分解活性はPROTAZYME AK TABLETS (Megazyme社製)を用いて測定した。AK1錠に対して10mMCaCl2200mMトリス緩衝液にて懸濁した基質溶液を撹拌しながら1.5mLチューブに300μL分注し氷上に置いた。分注した基質溶液に酵素液100μLを添加混合し、40℃に合わせたバイオシェーカーにて30分間撹拌することで反応させた。反応30分後、2%リン酸三ナトリウム溶液1mLを添加することで酵素反応を停止させ、遠心分離(13000g, 10分間)した。上清200μLをマイクロタイタープレートに移し、590nmの吸光度を測定した。30分間で上昇した590nm値でカゼイン分解活性の強度を判断した。
段階希釈した酵素液とゼラチン(終濃度2%ゼラチン)を12時間反応させた後、10分間煮沸することで反応を停止した。この反応停止液を超純水にて10倍希釈した後にSuperdex peptide7.5/300にてゲル濾過分析を行うことでCTP生成量を確認した。ゲル濾過の条件は以下の通りである。
Superdex_peptide7.5/300
バッファー:0.25 M NaCl 含有 0.02 M リン酸 buffer, pH 7
流速:0.28mL/min
アプライ量:100μL
検出:214 nm
システム:AKTA/ 低温庫
1.7128株コラゲナーゼ酵素粉末の調製
参考例の「1.コラゲナーゼ産生株のスクリーニング」により、コラゲナーゼ生産菌Lysinibacillusfusiformis 7128株を選抜した。
ジャーファーメンター(30L容)に20Lのゼラチン含有培地(5%フィッシュゼラチン、0.5%酵母エキス、2%NaCl)を調製、蒸気殺菌し、これに一晩SCD培地で培養した7128株200mLを添加後、30℃、撹拌数200rpm、通気量0.5vvmで36時間培養した。得られた培養液を珪藻土濾過に供し粗酵素液を得た。この粗酵素液を1%活性炭でろ過し、清澄ろ液を得た。この清澄ろ液を限外ろ過(分画分子量6000)に供し、4倍量の水を添加し脱塩濃縮した。これを珪藻土ろ過、メンブレンフィルターろ過(0.45μm)に供し、得られたろ液を凍結乾燥させ、これを7128株コラゲナーゼ酵素粉末とした。
57413株由来コラゲナーゼの配列情報と基に設計したプライマーを用いて遺伝子配列を確認した。遺伝子配列からアミノ酸配列も決定した。
配列番号1のアミノ酸配列はLysinibacillus fusiformis7128株由来のコラゲナーゼのアミノ酸配列(成熟体)である。尚、シグナルペプチドとプロ配列も有する、Lysinibacillus fusiformis7128株由来のコラゲナーゼのアミノ酸配列を配列番号2に示す。
配列番号3のDNAは、成熟体のアミノ酸配列(配列番号1)のみをコードするものであり、配列番号4のDNAは、成熟体(配列番号1のアミノ酸配列)に加え、シグナルペプチドとプロ配列をコードしている。
<配列番号1>
AEKTPYNVLQMKPIGIEMSKDEMVHSTMAEETLSYEERLEMGDFSQRPAPIMEQMDTQQLQEQYSMAELNNMSNRELIHTLGSIRWYQITDLFQFNDDTKAFYQNEERMQVIINELGNRGSSFTKDDSKGIETFVEVLRSAFYVAFYNNELGYLNERSFQDKCLPALNEIAKNPNFKLGTDEQDKVVSAYGKLIGNASSDVETVQHATNILKQYNENLSTYESENSKGQAIYDIIHGIDYDLQSYLYDTRKEANTTMWYGKIDSFIEEVNNIALIHNVTDSNSWLINNGIYYAGRLGQFHSNPNKGLEVVSQAMHMYPYLSEAYFVAVEQITTNYGGRDLNGNTVDLQKVREEGKKQYLPKTYTFDDGSIVFKTGDQVTEDKIQRLYWAAKEVKAQYHRVIGNDQALEPGNADDILTVVIYNSPDQYRLNRQLYGYETNNGGIYIEETGTFFTYERTPEQSIYSLEELFRHEYTHFLQGRFEVPGLFGTGDMYQNERLTWFQEGNAEFFAGSTRTNDVVPRKSIISGLSHDPSQRYTAEQTMFATYGSWDFYNYSFALQSYMYTHQFDMFDRIQDLIRANDVKNYDAYRDTLSKDSQLNMEYQAYMQQLIDNQETYEVPQVAEDYLMPHEPKALNEVQQEIVDIAHVKDANMTKHQSQFFNTFTLEGTYVGSATQGESQDWKTMSKQVNQMLEQLSQKEWSGYKTMTAYFVNYRVNAANQFEYDVVFHGVSTDDGETQAPIVQVNGPYTGMINEKIQFNSDGSKDTDGEIVSYLWDFGDGATSEAANPTHVYENEGTYKVTLTVKNNKGQESKGQTTATVQKGGQTGQEHAMTIPFNKPIKGSLIENDTNVYQFDITSLEEIDISVVNENQIGMTWVLYHESDKENYVAYGQEDGQTIKGKYNAKPGKYYLYVYKFDDENGTYTVQVQNSTKTEIEPNNRPEEATMLPFHTPLSGSLMEDDHTDVYEFNVTSPKEIDISVLNENQIGMTWVLYHESDSQNYASFGQEDGNMINGKLNAKPGKYYLYVYKFENENGTYTVHVQ
(1)至適温度
本酵素の反応性に対する温度の影響を確認した。Pz-peptideを基質とした測定法を用い、反応時の温度を4℃から60℃まで変化させて活性を測定した。最大活性(活性の最高値)を100%とした相対活性(Relative activity)で評価した。図1に示す通り、至適温度は40℃付近であった。
本酵素の温度安定性を調べた。本酵素液を200mM PIPES緩衝液(pH7.0)で5倍希釈したサンプルを各温度(4℃、20℃、30℃、40℃、50℃、60℃)で30分間処理した後にPz-peptideを基質とした測定法にて活性を測定した。最も活性が高かった処理温度での活性を100%とした相対残存活性(Relative residual activity)で評価した。図2に示す通り、4℃処理から40℃処理までは活性低下はなく、40℃まで安定であることがわかった。
本酵素の反応性に対するpHの影響を調べた。Pz-peptideを溶解する緩衝液を200mMの各緩衝液(pH4、5、6は酢酸緩衝液、pH6、7はPIPES緩衝液、pH7、8、9はトリス塩酸緩衝液、pH9、10、11はグリシン緩衝液とし、活性を測定した。最大活性を100%とした相対活性(Relative activity)で評価した。図3に示す通り、至適pHは7付近であることがわかった。
本酵素のpH安定性を調べた。本酵素溶液を200mMの各緩衝液(pH4、5、6は酢酸緩衝液、pH6、7はPIPES緩衝液、pH7、8、9はトリス塩酸緩衝液、pH9、10、11はグリシン緩衝液を使用)で5倍希釈し、30℃で60分間処理した後、Pz-peptideを基質とした測定法にて活性を測定した。最も活性が高かった処理pHでの活性を100%とした相対残存活性(Relative residual activity)で評価した。図4に示す通り、pHが約6~約9 (Tris-HCl)の範囲で高い活性(80%以上)を維持しており、当該pH域で安定であることがわかった。
7128株コラゲナーゼ(本発明の酵素)、57413株コラゲナーゼ及び比較用のStreptomyces由来コラゲナーゼを用いて、コラーゲントリペプチドの生成を確認した。
段階希釈した酵素液と終濃度2%の魚ゼラチン又は終濃度2%の牛骨ゼラチン)を40℃で12時間反応させた後、10分間煮沸することで反応を停止した。この反応停止液を超純水にて10倍希釈した後にSuperdex peptide7.5/300にてゲル濾過分析を行うことでCTP生成量を確認した。ゲル濾過の条件は以下の通りである。
バッファー:0.25 M NaCl 含有 0.02 M リン酸 buffer, pH 7
流速:0.28mL/min
アプライ量:100μL
検出:214 nm
システム:AKTA/ 低温庫
本発明の酵素は、Gly-Pro- Hyp、Gly-Pro-Ala、Gly-Glu-Argの生成能を示すことを見出した。特に、Gly-Glu-Argの生成能が優れていることを見出した。
5mm角にカットした鶏むね軟骨0.44gに8mg/mLの酵素溶液5mLを添加して、37℃で1.5時間振とう処理した。処理サンプルをガーゼでろ過して残渣を回収した。残渣を精製水で洗浄後、一晩室温で放置して乾燥させた。乾燥残渣の重量を測定した。ブランクとして、酵素溶液の代わりに精製水を用いて同様に実施した。比較対象として、57413株由来コラゲナーゼと市販の肉軟化剤である「スジまでやわらか職人」(株式会社キティー)を使用して同様に実施した。軟骨分解度を以下の式で算出した。
結果を図9に示す。
本発明の7128株由来のコラゲナーゼは、優れた軟骨分解能を有することが示された。
配列番号10:人工配列の説明:リバースプライマー
Claims (10)
- 配列番号1のアミノ酸配列又はそれと等価なアミノ酸配列からなるコラゲナーゼを有効成分とする、コラーゲントリペプチド製造のための酵素剤。
- 等価なアミノ酸配列からなるコラゲナーゼが、配列番号1のアミノ酸配列と90%以上の同一性を有し、配列番号1のアミノ酸配列からなるコラゲナーゼと牛骨ゼラチンからのGly-Glu-Argの生成能が同等であるコラゲナーゼである、請求項1に記載の酵素剤。
- コラゲナーゼがLysinibacillus fusiformis由来である、請求項1又は2に記載の酵素剤。
- Lysinibacillus fusiformisに由来し、以下の理化学的性質を有するコラゲナーゼを有効成分とする、コラーゲントリペプチド製造のための酵素剤。
(1)至適温度:40℃付近である。
(2)温度安定性:最も活性が高かった処理温度での活性を100%とした相対残存活性について4℃から40℃までは80%以上であり、50℃では10%以下である。
(3)至適pH:至適pHは7付近である。
(4)pH安定性:最も活性が高かった処理pHでの活性を100%とした相対残存活性について、pHが6~8の範囲では80%以上であり、pH5では10%以下である。 - 配列番号1のアミノ酸配列又はそれと等価なアミノ酸配列からなるコラゲナーゼを有効成分とする、食肉軟化及び/又は軟骨分解のための酵素剤。
- 等価なアミノ酸配列からなるコラゲナーゼが、配列番号1のアミノ酸配列と90%以上の同一性を有し、配列番号1のアミノ酸配列からなるコラゲナーゼと鶏軟骨分解能が同等であるコラゲナーゼである、請求項5に記載の酵素剤。
- コラゲナーゼがLysinibacillus fusiformis由来である、請求項5又は6に記載の酵素剤。
- Lysinibacillus fusiformisに由来し、以下の理化学的性質を有するコラゲナーゼを有効成分とする、食肉軟化及び/又は軟骨分解のための酵素剤。
(1)至適温度:40℃付近である。
(2)温度安定性:最も活性が高かった処理温度での活性を100%とした相対残存活性について4℃から40℃までは80%以上であり、50℃では10%以下である。
(3)至適pH:至適pHは7付近である。
(4)pH安定性:最も活性が高かった処理pHでの活性を100%とした相対残存活性について、pHが6~8の範囲では80%以上であり、pH5では10%以下である。 - 請求項1から4の何れか一項に記載の酵素剤をコラーゲン又はゼラチンに作用させることを特徴とする、コラーゲントリペプチドの製造方法。
- 請求項5から8の何れか一項に記載の酵素剤を食肉及び/又は軟骨に作用させることを特徴とする、食肉軟化及び/又は軟骨分解方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22876181.3A EP4410981A1 (en) | 2021-09-28 | 2022-09-27 | Enzyme agent for collagen tripeptide production or cartilage degradation |
JP2023551502A JPWO2023054315A1 (ja) | 2021-09-28 | 2022-09-27 | |
CN202280065067.6A CN118159651A (zh) | 2021-09-28 | 2022-09-27 | 用于制造胶原三肽或者分解软骨的酶剂 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021157337 | 2021-09-28 | ||
JP2021-157337 | 2021-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023054315A1 true WO2023054315A1 (ja) | 2023-04-06 |
Family
ID=85782699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/035843 WO2023054315A1 (ja) | 2021-09-28 | 2022-09-27 | コラーゲントリペプチド製造又は軟骨分解のための酵素剤 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4410981A1 (ja) |
JP (1) | JPWO2023054315A1 (ja) |
CN (1) | CN118159651A (ja) |
WO (1) | WO2023054315A1 (ja) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0516832B2 (ja) | 1984-03-09 | 1993-03-05 | Akira Endo | |
JPH0870853A (ja) | 1994-09-05 | 1996-03-19 | Nippi:Kk | ビブリオ属に属する新規な微生物ならびに当該微生物から生産される新規なコラーゲン分解酵素およびその利用 |
JP2001131084A (ja) * | 1999-11-05 | 2001-05-15 | Fancl Corp | 生体コラーゲン合成促進剤 |
JP2001510331A (ja) | 1996-11-19 | 2001-07-31 | ロシュ ダイアグノスティックス ゲーエムベーハー | クロストリジウム・ヒストリチカム由来の組換えコラゲナーゼタイプ▲i▼および細胞と細胞群の単離へのその使用 |
JP2002255847A (ja) * | 2001-02-26 | 2002-09-11 | Miyagi Kagaku Kogyo Kk | コラーゲン産生促進剤、それを含む機能性食品および医薬品 |
JP2010263880A (ja) | 2009-04-16 | 2010-11-25 | Nippi:Kk | 微生物由来の新規コラゲナーゼ遺伝子 |
JP2013034423A (ja) * | 2011-08-05 | 2013-02-21 | Guthy-Renker Japan Co Ltd | 健康食品 |
JP2018183106A (ja) | 2017-04-27 | 2018-11-22 | 株式会社ニッピ | コラーゲン、ゼラチンおよびコラーゲン加水分解物に含まれるGly−X−Y配列量の測定方法、およびX−Y配列量の測定方法 |
-
2022
- 2022-09-27 EP EP22876181.3A patent/EP4410981A1/en active Pending
- 2022-09-27 CN CN202280065067.6A patent/CN118159651A/zh active Pending
- 2022-09-27 WO PCT/JP2022/035843 patent/WO2023054315A1/ja active Application Filing
- 2022-09-27 JP JP2023551502A patent/JPWO2023054315A1/ja active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0516832B2 (ja) | 1984-03-09 | 1993-03-05 | Akira Endo | |
JPH0870853A (ja) | 1994-09-05 | 1996-03-19 | Nippi:Kk | ビブリオ属に属する新規な微生物ならびに当該微生物から生産される新規なコラーゲン分解酵素およびその利用 |
JP2001510331A (ja) | 1996-11-19 | 2001-07-31 | ロシュ ダイアグノスティックス ゲーエムベーハー | クロストリジウム・ヒストリチカム由来の組換えコラゲナーゼタイプ▲i▼および細胞と細胞群の単離へのその使用 |
JP2001131084A (ja) * | 1999-11-05 | 2001-05-15 | Fancl Corp | 生体コラーゲン合成促進剤 |
JP2002255847A (ja) * | 2001-02-26 | 2002-09-11 | Miyagi Kagaku Kogyo Kk | コラーゲン産生促進剤、それを含む機能性食品および医薬品 |
JP2010263880A (ja) | 2009-04-16 | 2010-11-25 | Nippi:Kk | 微生物由来の新規コラゲナーゼ遺伝子 |
JP2013034423A (ja) * | 2011-08-05 | 2013-02-21 | Guthy-Renker Japan Co Ltd | 健康食品 |
JP2018183106A (ja) | 2017-04-27 | 2018-11-22 | 株式会社ニッピ | コラーゲン、ゼラチンおよびコラーゲン加水分解物に含まれるGly−X−Y配列量の測定方法、およびX−Y配列量の測定方法 |
Non-Patent Citations (12)
Title |
---|
"Current protocols in molecular biology", 1987, COLD SPRING HARBOR LABORATORY PRESS |
CHUNG, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA., vol. 86, 1989, pages 2172 |
DATABASE UniProtKB/TrEMBL 8 May 2019 (2019-05-08), ANONYMOUS : " Microbial collagenas", XP093053391, retrieved from Uniprot Database accession no. A0A410MLN5 * |
FELGNER, P. L. ET AL., PROC. NATL., vol. 84, 1984, pages 7413 - 7417 |
GENE, vol. 96, 1990, pages 23 |
HOA BACH THI MAI, PHAM THANH HUYEN, DINH TRUONG SON, TAKAGI HIROSHI: "Characterization of collagenase found in the nonpathogenic bacterium Lysinibacillus sphaericus VN3", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, JAPAN SOCIETY FOR BIOSCIENCE, BIOTECHNOLOGY, AND AGROCHEMISTRY, JP, vol. 84, no. 11, 1 November 2020 (2020-11-01), JP , pages 2293 - 2302, XP093053394, ISSN: 0916-8451, DOI: 10.1080/09168451.2020.1799748 * |
J. MOL. BIOL., vol. 166, 1983, pages 557 |
JOURNAL OF MOLECULAR BIOLOGY (J. MOL. BIOL., vol. 53, 1970, pages 159 |
KARLINALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 68 |
KARLINALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 77 |
POTTER, H. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 81, 1984, pages 7161 - 7165 |
SHIMIZU, Y. ET AL., NATURE BIOTECH., vol. 19, 2001, pages 751 - 755 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2023054315A1 (ja) | 2023-04-06 |
CN118159651A (zh) | 2024-06-07 |
EP4410981A1 (en) | 2024-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3130671B1 (en) | New protein deamidase | |
EP0693556B1 (en) | Transglutaminase originating in japanese oyster | |
CN108699549B (zh) | β-半乳糖苷酶 | |
ES2595500T3 (es) | Nuevas proteasas que pueden hidrolizar péptidos y proteínas de gluten a un pH ácido, procedentes del actinomiceto Actinoallomurus | |
JP6161190B2 (ja) | 耐熱性ケラチナーゼ酵素、その製造方法、およびそれをコードするdna | |
JP5006380B2 (ja) | 新規なα−ガラクトシダーゼ | |
JP5447761B2 (ja) | キチン・キトサンを分解する新種の微生物及びその利用方法 | |
JP4663631B2 (ja) | 放線菌由来のampデアミナーゼ及びその利用 | |
JPWO2009087826A1 (ja) | シュウ酸脱炭酸酵素の生産に利用される組換え発現プラスミドベクター及び組換え菌、並びに組換えシュウ酸脱炭酸酵素の生産方法 | |
JP5392942B2 (ja) | 新規なアルカリアルギン酸リアーゼとその利用 | |
WO2021200955A1 (ja) | コラゲナーゼ剤及びその用途 | |
CN107460176B (zh) | 一种过氧化物酶DyP35基因及其表达蛋白和应用 | |
WO2023054315A1 (ja) | コラーゲントリペプチド製造又は軟骨分解のための酵素剤 | |
JP5094461B2 (ja) | ヒアルロン酸加水分解酵素をコードする遺伝子 | |
WO2021256518A1 (ja) | 新規トランスグルタミナーゼ | |
JP4259169B2 (ja) | 新規α−1,2−マンノシダーゼおよびその遺伝子、ならびに該酵素を用いたα−マンノシル糖化合物の製造方法 | |
JPWO2012111810A1 (ja) | キチン分解酵素遺伝子および該遺伝子によりコードされるキチン分解酵素 | |
JP6821155B2 (ja) | L−リシンα−オキシダーゼの製造方法 | |
CN116323937A (zh) | 使用了新型酮糖-3-差向异构酶的酮糖的制造方法 | |
WO2024071388A1 (ja) | 酵素剤及びその応用 | |
WO2022264963A1 (ja) | トランスグルタミナーゼを含む酵素剤及びその用途 | |
WO2021193749A1 (ja) | ペプチドグリカン分解活性を有するタンパク質および該タンパク質をコードするdna、微生物分解製剤ならびに微生物分解方法 | |
JP2011152075A (ja) | D−,l−ペプチドの立体選択的合成法 | |
JP2023027412A (ja) | エラスチン分解酵素 | |
JP2023057968A (ja) | ヒドロキシプロリル-グリシンの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22876181 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023551502 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280065067.6 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022876181 Country of ref document: EP Effective date: 20240429 |